USSTOCK.TODAY
Regular Market
Log in Sign up

Citadel Advisors Increases Stake in AbbVie and Juvymo Approval

The Motley Fool +1 · ·by G4L

ABBV Abbvie Inc
$294.83 +3.09%
View chart & analysis →
  1. 1Citadel Advisors purchased 2.7 million shares of AbbVie in the second quarter.
  2. 2The U.S. Food and Drug Administration approved Juvymo in September.
  3. 3AbbVie acquired Cerevel Therapeutics in 2024.

So what's the key point?

Citadel Advisors bought an additional 2.7 million shares of AbbVie. This follows the approval of a new drug in the United States, which increased AbbVie's value.

Source The Motley Fool +1 · View original ↗

Related 3-line summaries

AbbVie signs $757 million licensing deal with Bryce Pharma for migraine treatment Pharmaceutical Technology · 23h agoAbbVie confirms efficacy of combination therapy in Phase 2 trial of Crohn's disease treatment ABBV-466 The Motley Fool +1 · 3d agoAbbVie reports third-quarter results beating estimates and announces dividend increase The Motley Fool +1 · 5d ago
Today's 5 AI picks, all free
Nothing hidden: past picks and how they did against the S&P 500.
See today's picks →
← Back to news